E-Therapeutics PLC represents values of innovation, scientific excellence, and collaboration in the field of therapeutics. The company's corporate philosophy revolves around utilizing network pharmacology and computational biology to discover and develop novel drugs. E-Therapeutics PLC is committed to leveraging advanced technology and big data to identify new therapeutic targets and accelerate the drug discovery process. With a focus on precision medicine, the company aims to address unmet medical needs and improve patient outcomes. E-Therapeutics PLC's dedication to scientific rigor and strategic partnerships allows it to remain at the forefront of innovative drug development.

E-Therapeutics PLC is primarily present in the United Kingdom.

E-Therapeutics PLC has achieved significant milestones in their journey. This dynamic company has successfully developed innovative therapies that have garnered attention in the healthcare industry. E-Therapeutics PLC has consistently showcased their commitment to research and development, resulting in groundbreaking pharmaceutical advancements. Their pioneering work has led to notable achievements such as the successful completion of clinical trials, regulatory approvals for their therapies, and strategic collaborations with renowned organizations. E-Therapeutics PLC's remarkable progress has solidified their position as a leading player in the market, revolutionizing the field of therapeutics and positively impacting the lives of patients worldwide.

E-Therapeutics PLC is a leading biotechnology company based in the United Kingdom. Founded in 2003, the company focuses on the discovery and development of novel drugs using its proprietary network-driven drug discovery (NDD) platform. E-Therapeutics PLC combines approaches from network pharmacology, computational biology, and artificial intelligence to identify promising drug candidates. With a team of expert scientists and partnerships with leading academic institutions, E-Therapeutics PLC has made significant advancements in various therapeutic areas, including oncology and neuroscience. The company's innovative approach and dedication to scientific excellence have positioned it as a key player in the biotech industry.

The main competitors of E-Therapeutics PLC in the market include pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and Johnson & Johnson. These industry giants have a strong presence and compete with E-Therapeutics in various therapeutic areas, including drug discovery and development. Additionally, other smaller biotechnology companies focusing on similar research and product pipelines also pose competition to E-Therapeutics.

E-Therapeutics PLC is primarily active in the pharmaceutical and biotechnology industries.

The business model of E-Therapeutics PLC focuses on utilizing network pharmacology and computational methods to identify novel drug candidates for a range of diseases. By leveraging its proprietary drug discovery platform, E-Therapeutics aims to accelerate the development of more effective and targeted therapies. The company collaborates with pharmaceutical partners and academic institutions to advance its drug discovery programs. E-Therapeutics utilizes a data-driven approach, analyzing vast amounts of biological and chemical data to identify potential drug targets and optimize treatment options. This enables E-Therapeutics PLC to provide innovative solutions in the field of drug discovery.

De E-Therapeutics K/W is -5,22.

De E-Therapeutics KUV is 93,91.

De AlleAktien Kwaliteitsscore voor E-Therapeutics is 4/10.

De verwachte E-Therapeutics omzet is 515.000,00 GBP.

De verwachte E-Therapeutics winst is -9,27 mln. GBP.

E-Therapeutics PLC is an innovative biotech company based in the UK. The company's business model is based on the discovery and development of novel drugs for the treatment of serious diseases such as cancer, inflammation, and neurological disorders. E-Therapeutics uses a unique computer-based platform that allows for the simulation and analysis of complex biological systems and disease processes. The key focus of E-Therapeutics is the discovery of new drugs. The company utilizes its innovative network pharmacology platform to analyze the complex relationship between genetic factors, signaling pathways, and drug effects. Based on this analysis, E-Therapeutics systematically develops new drugs that specifically target certain signaling pathways and thus influence underlying disease processes. Another important aspect of E-Therapeutics is the clinical development of new drugs. The company works closely with clinical partners and contract research organizations to test its drugs in clinical trials and demonstrate their efficacy and safety. E-Therapeutics employs a strategic pipeline planning approach to ensure that the most promising drugs are quickly and efficiently advanced into clinical development. In addition to drug discovery and development, E-Therapeutics also offers consulting and services in the field of network pharmacology. The company supports industry and academic research partners in the analysis and interpretation of complex data, as well as the identification of new target structures and drug candidates. One example of a product from E-Therapeutics' pipeline is the drug ETX-155, which is being developed for the treatment of cancer. ETX-155 specifically targets the p38 signaling pathway, which plays an important role in many types of cancer. In preclinical studies, ETX-155 has already shown promising results and is currently in Phase I clinical development. Overall, E-Therapeutics' business model provides a promising basis for the development of new, effective drugs based on the latest technologies and analytical methods. The company relies on collaborative partnerships with clinical partners and contract research organizations to quickly and efficiently bring its drugs to market and make a significant contribution to improving healthcare. The answer is E-Therapeutics PLC is an innovative biotech company based in the UK that focuses on the discovery and development of novel drugs for the treatment of serious diseases such as cancer, inflammation, and neurological disorders. The company utilizes a computer-based platform to simulate and analyze complex biological systems and disease processes. E-Therapeutics also offers consulting and services in network pharmacology. They have a drug in their pipeline, ETX-155, being developed for cancer treatment, which targets the p38 signaling pathway. The company works closely with clinical partners and contract research organizations to test and develop their drugs efficiently.

E-Therapeutics keert een dividend van 0 GBP uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor E-Therapeutics of het bedrijf keert geen dividend uit.

De ISIN van E-Therapeutics is GB00B2823H99.

Het WKN van E-Therapeutics is A0M8VQ.

De ticker van E-Therapeutics is ETX.L.

Binnen de laatste 12 maanden betaalde E-Therapeutics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal E-Therapeutics naar verwachting een dividend van 0 GBP betalen.

De dividendrendement van E-Therapeutics is momenteel .

E-Therapeutics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

E-Therapeutics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 GBP verwacht. Dit komt overeen met een dividendrendement van 0 %.

E-Therapeutics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van E-Therapeutics van 19-11-2024 ter hoogte van 0 GBP te ontvangen, moest je het aandeel voor de ex-datum op 19-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 19-11-2024.

In het jaar 2023 heeft E-Therapeutics 0 GBP aan dividenden uitgekeerd.

De dividenden van E-Therapeutics worden in GBP uitgekeerd.